Self-administrated vaginal 2% lidocaine in-situ gel for pain relief during copper intrauterine device insertion in women with previous caesarean delivery only: a randomised, double-blind placebo-controlled trial.

Autor: Abbas AM; Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt., Abd Ellah NH; Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt., Hosny MA; Department of Obstetrics and Gynecology, Obstetrics, Gynecology and Pediatrics Hospital, Assiut, Egypt., Abdellah MS; Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt., Ali MK; Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Jazyk: angličtina
Zdroj: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception [Eur J Contracept Reprod Health Care] 2021 Apr; Vol. 26 (2), pp. 132-138. Date of Electronic Publication: 2021 Feb 04.
DOI: 10.1080/13625187.2020.1868427
Abstrakt: Objective: To evaluate the analgesic effect of self-administered vaginal 2% lidocaine in-situ gel in pain relief during copper intrauterine device (IUD) insertion in women with previous caesarean delivery only.
Methods: A Randomised, double-blind, placebo-controlled trial (Clinicaltrials.gov: NCT03166111) included reproductive-aged women who previously delivered only by caesarean section (CS) requesting Copper IUD insertion. Eligible women were recruited and randomised (1:1) to lidocaine in-situ gel vs. placebo. Each woman was supplied by a syringe filled with five ml lidocaine or placebo in-situ gel to be self-administered vaginally ten minutes before insertion. The primary outcome was the difference in pain scores during IUD placement using a 10-cm Visual Analogue Scale (VAS).
Results: The final analysis included 216 women ( n  = 108 in each arm). Women in the Lidocaine in situ gel group were more likely to report statistically significant lower pain scores during vulsellum application, uterine sound placement, and during IUD placement [Mean difference (95%CI) = 2.04 (1.66-2.42), 2.62 (2.20-3.04), and 2.57 (2.12-3.01), respectively, p  = 0.0001]. A significantly lower IUD insertion score indicating easier insertion was reported in the lidocaine group ( p  = 0.004). Similarly, the duration of IUD insertion was significantly shorter in the lidocaine group ( p  = 0.008). There was a higher level of satisfaction in the lidocaine group (5.92 vs. 3.34) in the placebo group ( p  = 0.0001).
Conclusions: Self-administered vaginal lidocaine in-situ gel 10 min before copper IUD insertion is effective in pain reduction in women with previous caesarean delivery only.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje